Publications by authors named "Samuel Large"

Claim this Profile
T
The Hidden Economic Consequences of Migraine to the UK Government: Burden-of-Disease Analysis Using a Fiscal Framework.
Rui Martins, Samuel Large, Rachel Russell, Gary Surmay, Mark P Connolly

J Health Econ Outcomes Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy.
Mark H Rozenbaum, Samuel Large, Rahul Bhambri, Michelle Stewart, Robert Young

J Comp Eff Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review.
Mark H Rozenbaum, Samuel Large, Rahul Bhambri, Michelle Stewart, Jo Whelan

Cardiol Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing the Fiscal Consequences of Controlled and Uncontrolled Osteoarthritis Pain Applying a UK Public Economic Perspective.
Rui Martins, Nikos Kotsopoulos, Melodi Kosaner Kließ, Craig Beck, Lucy Abraham, Samuel Large

J Health Econ Outcomes Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK.
Claire Telford, Evelina Bertranou, Samuel Large, Hilary Phelps, Mattias Ekman

Pharmacoecon Open· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin's lymphoma: a United States payer perspective.
Samuel Large, Robert Hettle, Arun Balakumaran, Elise Wu, Rebekah H Borse

J Med Econ· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.
Evelina Bertranou, Carolyn Bodnar, Viktor Dansk, Alastair Greystoke, Samuel Large

J Med Econ· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis